https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-relapsed-multiple-myeloma-likelihood-of-approval/?utm_source=lgp5-loa&utm_medium=24-228846&utm_campaign=recommended-articles-pi
Sonrotoclax is under clinical development by BeiGene and currently in Phase II for Relapsed Multiple Myeloma.
multiple myelomasonrotoclaxbeigenerelapsedlikelihood